Tocqueville Asset Management L.P. Bei Gene, Ltd. Transaction History

Tocqueville Asset Management L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 Apr 30, 2019	SELL	$122.82 - $151.83 $186,072 - $230,022	-1,515 Closed	0 $0
Q4 2018 Feb 08, 2019	SELL	$107.01 - $175.15 $371,859 - $608,646	-3,475 Reduced 69.64%	1,515 $212,000
Q3 2018 Nov 13, 2018	BUY	$152.62 - $189.66 $532,643 - $661,913	3,490 Added 232.67%	4,990 $859,000
Q1 2018 May 14, 2018	BUY	$97.41 - $177.22 $146,115 - $265,830	1,500 New	1,500 $252,000

254

42.4M

135K

111K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $23.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Tocqueville Asset Management L.P., based on Form 13F filings with the SEC.

Stay updated on Tocqueville Asset Management L.P. with notifications on news.